Senti Biosciences Holdings, Inc.

Senti Biosciences operates with a fragile capital structure, holding $8.94 million in cash and equivalents against total liabilities of $35.68 million and total equity of $2.57 million. The current ratio stands at 1.04, indicating minimal liquidity buffer, while the debt-to-equity ratio is reported as 0.0, suggesting liabilities are primarily non-debt obligations such as payables or accrued expenses. The company faces high liquidity risk, with filings explicitly referencing going-concern or substantial-doubt language, noting that financial statements do not include adjustments necessary if the company were unable to continue as a going concern. The market capitalization of $29.73 million implies a price-to-book ratio of 11.59, reflecting a significant premium over tangible book value despite negative earnings.

Profitability metrics are deeply negative, with a return on equity of -23.95% and return on assets of -1.61%. The company reported a net loss of $4.22 million on revenue of $16,000 in Q1 2026, resulting in an operating loss of $4.62 million. Operating cash flow was negative $7.48 million, highlighting a substantial cash burn rate relative to its asset base. The EV/EBITDA ratio is negative, and EV/Revenue is 945.35, indicating that the market values the company based on future potential rather than current financial performance. Without cohort median data for direct comparison, these metrics are consistent with early-stage biotech firms that have not yet achieved commercial scale.

Revenue concentration is effectively total, with the $16,000 reported in Q1 2026 likely stemming from minor licensing or collaboration fees rather than product sales. The company does not disclose detailed segment or geographic revenue breakdowns in the provided data, implying a single operating segment focused on R&D and clinical development. The lack of diversified revenue streams underscores the company's dependence on successful clinical outcomes and potential strategic partnerships to generate future income.

Growth trajectory is characterized by negligible revenue generation and consistent net losses. The Q1 2026 revenue of $16,000 represents a minimal commercial footprint, with no historical period data provided to assess year-over-year trends. The company's primary growth driver is the advancement of its pipeline, particularly SENTI-202, through clinical trials. The absence of significant revenue growth suggests that the company remains in the pre-commercial phase, with value creation dependent on regulatory milestones and potential acquisition or partnership events.

Risk factors are elevated, with high liquidity risk and low dilution risk noted in the assessment. Key flags include a current ratio close to the minimum comfort range and explicit going-concern language in filings. The company faces significant operational risks, including the ability to raise financing, maintain Nasdaq listing, and successfully complete clinical trials for SENTI-202. Regulatory risks are inherent in the pharmaceutical industry, with the company relying on FDA guidance for expansion cohorts in oncology trials. The potential for supply chain disruptions and global health crises further complicates the operational outlook.

Recent events highlight critical listing risks, with the stock price falling below $1.00 to $0.96, triggering a high-severity alert for US continued-listing minimum-bid threshold compliance. The stock has traded below $1.00 for 19 consecutive days, posing a threat to its Nasdaq listing status. Analyst sentiment remains positive, with a mean price target of $11.25 and a mean recommendation of 1.75 (strong buy), suggesting a significant disconnect between current market price and analyst expectations. The company continues to navigate the complexities of early-stage development while managing immediate liquidity and listing compliance challenges.

Analysts project 1,034% upside to a mean price target of $11.00, signaling strong institutional confidence in future value.

The company maintains a zero debt-to-equity ratio, eliminating interest expense risks and preserving capital for operational flexibility.

Capital expenditure intensity ranks best-in-class within the biotechnology cohort, suggesting efficient investment in growth infrastructure.

Dilution risk is assessed as low, providing relative protection to existing shareholders against aggressive equity issuance.

Free cash flow burn improved slightly year-over-year, indicating modest progress in managing operational cash outflows.

High liquidity risk flags indicate potential difficulties in meeting short-term financial obligations without external capital.

Return on equity of -23.95% significantly underperforms the cohort median, demonstrating poor capital efficiency.

Operating margin of -3,126% ranks in the bottom quartile, reflecting severe inefficiencies in core business operations.

Revenue $16.0k; Operating income -$4.6M.

• ▍Revenue $16.0k
• ▍Operating income -$4.6M
• ▍Net margin -26381.2%

Operating income -$50.1M.

• ▍Operating income -$50.1M

Operating income -$33.2M.

• ▍Operating income -$33.2M

Revenue $22.0k; Operating income -$68.8M.

• ▍Revenue $22.0k
• ▍Operating income -$68.8M
• ▍Net margin -279263.6%

Revenue $0.00; Operating income -$61.0M.

• ▍Revenue $0.00
• ▍Operating income -$61.0M

Revenue $0.00; Operating income -$61.0M.

• ▍Revenue $0.00
• ▍Operating income -$61.0M

Revenue $2.0M; Operating income -$92.7M.

• ▍Revenue $2.0M
• ▍Operating income -$92.7M
• ▍Net margin -3592.4%

Revenue $2.0M; Operating income -$92.7M.

• ▍Revenue $2.0M
• ▍Operating income -$92.7M
• ▍Net margin -3592.4%